Prostate Cancer Treatment Updates

Expert oncologists Evan Y. Yu, MD; Andrew J. Armstrong, MD, MSc; Pedro C. Barata, MD, MSc; Tanya B. Dorff, MD; and Mary-Ellen Taplin, MD, review data from ASCO 2022 and discuss updates on the management of prostate cancer.

EP. 1: Clinical Scenario 1: A 67-Year-Old With Metastatic HSPC

June 28th 2022

Centering discussion on a clinical scenario of metastatic hormone-sensitive prostate cancer, expert panelists consider how they might approach frontline therapy in this setting.

EP. 2: Optimizing Management of mHSPC: Multimodality Care and Genetic Testing

June 28th 2022

A brief review of the respective roles of multidisciplinary care and genetic testing in patients diagnosed with metastatic hormone-sensitive prostate cancer.

EP. 3: Factors in Selecting AR-Targeted Therapy for Patients With Metastatic HSPC

July 5th 2022

Expert perspectives on frontline AR-targeted therapy in metastatic hormone-sensitive prostate cancer, with deference to recent clinical trial data on triplet therapy.

EP. 4: Establishing Eligibility for Frontline AR-Targeted Therapy in mHSPC

July 5th 2022

Continuing their discussion on frontline AR-targeted therapy in mHSPC, experts define how accessibility and patient eligibility impact treatment selection.

EP. 5: Clinical Trial Data in Metastatic HSPC From the ASCO 2022 Annual Meeting

July 12th 2022

Expert panelists briefly share their excitement for trial data readouts in metastatic hormone-sensitive prostate cancer from the annual ASCO 2022 Annual meeting.

EP. 6: Improving Patient Monitoring in the Setting of Metastatic HSPC

July 12th 2022

Closing out their discussion on a clinical scenario of metastatic HSPC, expert panelists consider optimal patient monitoring strategies and novel imaging.

EP. 7: Clinical Scenario 2: A 64-Year-Old Man With nmCRPC

July 19th 2022

Shared insight on a clinical scenario of a patient with nonmetastatic castration-resistant prostate cancer who was treated with prostatectomy and adjuvant therapy.

EP. 8: Optimizing Management of nmCRPC: Patient Monitoring and Initiating Therapy

July 19th 2022

Expert perspectives on monitoring patients with nonmetastatic castration-resistant prostate cancer and deciding when to initiate systemic therapy.

EP. 9: Selecting Among Available AR Inhibitors in Nonmetastatic CPRC

July 26th 2022

A comprehensive discussion on factors that inform treatment selection of available AR-targeted therapy for patients with nonmetastatic CRPC.

EP. 10: Addressing Unmet Needs in Nonmetastatic CRPC

July 26th 2022

Before closing out their second module, panelists highlight remaining unmet needs in the setting of nonmetastatic castration-resistant prostate cancer.

EP. 11: Clinical Scenario 3: A 76-Year-Old With Metastatic CRPC

August 2nd 2022

Shared insight on a clinical scenario of metastatic castration-resistant prostate cancer managed with androgen-deprivation therapy and docetaxel.

EP. 12: Metastatic Castration-Resistant Prostate Cancer: Optimal Imaging Strategies

August 2nd 2022

Expert oncologists define appropriate imaging strategies, conventional and novel, in patients with metastatic castration-resistant prostate cancer.

EP. 13: Therapy Overview: Sequencing Agents in Patients With Metastatic CRPC

August 9th 2022

A comprehensive review of available agents in the setting of metastatic CRPC, with discussion of optimal sequencing in later lines of therapy.

EP. 14: PTEN Loss in mCRPC: Caution Surrounding mTOR, PI3K, and AKT Inhibition

August 9th 2022

Panelists share caution toward use of mTOR-, PI3K-, and AKT-targeted therapies in the setting of PTEN loss in metastatic CRPC.

EP. 15: An Overview of PARP Inhibition in Metastatic CRPC

August 16th 2022

Focusing on the advent of PARP inhibitors in metastatic castration-resistant prostate cancer, genitourinary cancer specialists provide an overview of clinical trials and agents in this setting.

EP. 16: Metastatic CRPC: Practical Selection and Use of PARP Inhibitors

August 16th 2022

Expert perspectives on how PARP inhibition will fit into the real-world management of patients with metastatic castration-resistant prostate cancer.

EP. 17: What is the Role of 177Lu-PSMA-617 in Metastatic CRPC?

August 23rd 2022

Panelists share insight on 177Lu-PSMA-617 and consider where it might fit into the treatment paradigm for metastatic castration-resistant prostate cancer.

EP. 18: Practical Considerations in Selecting Therapy for Metastatic CRPC

August 23rd 2022

Closing out their discussion on prostate cancer, expert panelists highlight which factors best inform selection of therapy for patients with mCRPC.

EP. 19: Optimizing Patient Selection for Cabazitaxel Therapy in Metastatic CRPC

December 26th 2022

A brief review of factors that may influence an academic or community physician’s choice to utilize cabazitaxel in the setting of metastatic castration-resistant prostate cancer.